Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Soleil Boughton sold 3,462 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $27.60, for a total value of $95,551.20. Following the transaction, the insider directly owned 293,886 shares in the company, valued at approximately $8,111,253.60. The trade was a 1.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Soleil Boughton also recently made the following trade(s):
- On Wednesday, October 14th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.06, for a total value of $100,576.66.
- On Wednesday, September 30th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.17, for a total value of $100,957.37.
- On Wednesday, September 16th, Soleil Boughton sold 6,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.86, for a total value of $173,734.96.
- On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.33, for a total value of $97,965.14.
- On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05.
Hims & Hers Health Price Performance
HIMS opened at $27.59 on Friday. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $48.34. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The company has a market capitalization of $6.44 billion, a price-to-earnings ratio of -43.79 and a beta of 2.44. The firm’s fifty day moving average price is $29.04 and its two-hundred day moving average price is $27.08.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter in the prior year, the company earned $0.17 EPS. The business’s revenue for the quarter was up 38.2% on a year-over-year basis. As a group, analysts anticipate that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Hims & Hers Health
A number of hedge funds and other institutional investors have recently made changes to their positions in HIMS. Greenfield Seitz Capital Management LLC increased its stake in shares of Hims & Hers Health by 4.6% during the 3rd quarter. Greenfield Seitz Capital Management LLC now owns 385,366 shares of the company’s stock worth $11,480,000 after purchasing an additional 17,027 shares during the last quarter. Kurv Investment Management LLC raised its holdings in shares of Hims & Hers Health by 25.9% in the 3rd quarter. Kurv Investment Management LLC now owns 65,274 shares of the company’s stock worth $1,945,000 after purchasing an additional 13,409 shares during the period. Prosperitas Financial LLC bought a new stake in shares of Hims & Hers Health in the 3rd quarter worth approximately $2,649,000. VestGen Advisors LLC raised its holdings in shares of Hims & Hers Health by 256.4% in the 3rd quarter. VestGen Advisors LLC now owns 20,578 shares of the company’s stock worth $613,000 after purchasing an additional 14,804 shares during the period. Finally, Evergreen Capital Management LLC purchased a new position in Hims & Hers Health in the third quarter valued at approximately $446,000. 63.52% of the stock is owned by hedge funds and other institutional investors.
Hims & Hers Health News Summary
Here are the key news stories impacting Hims & Hers Health this week:
- Positive Sentiment: U.S. Department of Health and Human Services reportedly used “enforcement discretion” to temporarily allow compounding of six peptides. The policy could improve Hims & Hers’ access to compounded treatments and support growth, although its temporary nature creates continuing uncertainty. Hims & Hers Jumped as HHS Uses Enforcement Discretion to Open Peptide Compounding
- Positive Sentiment: Earlier strength in telehealth stocks following Teladoc’s better-than-expected results provided some support for Hims & Hers and highlighted continued investor interest in digital-health companies. Teladoc Soars as Revenue and Profit Beat Estimates
- Neutral Sentiment: Insider Soleil Boughton sold 3,462 shares for approximately $95,551 under a pre-arranged Rule 10b5-1 trading plan. The transaction reduced the insider’s position by about 1.16% and is therefore a limited signal about management’s outlook. SEC Insider Trading Filing
- Negative Sentiment: Multiple law firms are soliciting investors ahead of the November 2, 2026 deadline to seek lead-plaintiff status in a federal securities class action covering purchases from August 4, 2025, through July 29, 2026. The litigation stems in part from allegations associated with an FTC complaint and could expose Hims & Hers to legal expenses, potential damages, reputational harm and further scrutiny. The repeated notices appear to be the primary near-term catalyst weighing on the stock. HIMS Securities Class Action Deadline Alert
Analysts Set New Price Targets
Several equities research analysts have commented on the stock. Bank of America increased their price objective on shares of Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research note on Tuesday, August 11th. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Barclays reduced their target price on Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a report on Friday, August 21st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Three research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $32.43.
View Our Latest Stock Analysis on HIMS
About Hims & Hers Health
Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.
Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.
Featured Articles
- Five stocks we like better than Hims & Hers Health
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
